Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics.
Lycia Therapeutics is seeking a highly motivated and creative scientific leader to advance its pipeline of LYTAC degraders and establish the company as the industry leader in endosomal-lysosomal degradation and delivery.
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics.
Kymera Therapeutics